Senior Director, Endocrinology Pharmacy Operations

Remote

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

The ideal candidate will have a strong background in market access and patient services within the pharmaceutical industry, with a focus on endocrinology. Preferred qualifications include experience with rare diseases, a deep understanding of patient support operations, and proficiency in managing specialty pharmacy relationships and financial assistance programs. Experience in contract negotiation and KPI management is also valued.

Responsibilities

The Senior Director of Endocrinology Pharmacy Operations will lead and strategize patient services for Corcept's core and pipeline products. This includes overseeing the Patient Support Hub, Field Reimbursement Specialists, and Specialty Pharmacy network to ensure seamless patient access and adherence. Responsibilities also encompass managing financial assistance programs, driving operational excellence, monitoring performance through KPIs, and ensuring compliance with all regulatory and corporate policies.

Skills

Patient Services

Pharmacy Operations

Strategic Planning

Team Leadership

Operational Excellence

Patient Access

Financial Assistance Programs

Reimbursement

Cortisol Modulators

Endocrinology

Pharmaceutical Industry

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free